Saturday, March 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Talking with Mr. Zach Baron, Director of the Health Policy and the Law Initiative at the O’Neill Institute

Launched in February 2023, the Health Care Litigation Tracker is a free digital resource that tracks and analyzes health care litigation in the United States. The tracker contains current health policy litigation cases, with an emphasis on health care access, coverage, affordability, transparency, and equity.

Zachary Baron is a director of the Health Policy and the Law Initiative at the O’Neill Institute. He focuses on providing technical assistance for policymakers and public education on health policy legal issues with an emphasis on access to coverage, affordability, transparency, and equity.

Cases discussed in the conversation are:

American College of Pediatricians et al. v. Becerra et al.

https://litigationtracker.law.georgetown.edu/litigation/american-college-of-pediatricians-et-al-v-becerra-et-al-2/

Barrows et al v. Humana, Inc.

https://litigationtracker.law.georgetown.edu/litigation/barrows-et-al-v-humana-inc/

Eli Lilly and Company et al. v. U.S. Department of Health and Human Services et al.

https://litigationtracker.law.georgetown.edu/litigation/eli-lilly-and-company-et-al-v-u-s-department-of-health-and-human-services-et-al/

 

#health #law #oneillinstitute #georgetown #policy

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!